 | • レポートコード：MRC23Q38794 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、119ページ • 納品方法：Eメール（2-3日） • 産業分類：医薬品 |
| Single User | ￥406,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥812,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界のがん治療薬市場について調査・分析し、世界のがん治療薬市場概要、メーカー別競争状況、地域別市場規模、タイプ別セグメント分析（化学療法薬品、分子標的治療薬品、免疫療法薬品、ホルモン療法薬品、その他）、用途別セグメント分析（血液がん、乳がん、消化器がん、前立腺がん、肺がん、その他）、主要企業のプロファイル、市場動向などに関する情報を掲載しています。主要企業としては、Novartis AG、CELGENE CORPORATION、Merck & Company Inc、Pfizer Inc.、Johnson & Johnson、Roche、GlaxoSmithKline plc、AstraZeneca、Teva Pharmaceutical Industries Ltd、Takeda、Astellas、NATCO Pharma Limited、Amgen、Ipsen、Aurobindo Pharma、Hikma Pharmaceuticals PLC、Mylan、Sanofi、Bayer、Biogen Idecなどが含まれています。世界のがん治療薬市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、がん治療薬市場規模を推定する際に考慮しました。本レポートは、がん治療薬の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、がん治療薬に関するビジネス上の意思決定に役立てることを目的としています。 ・がん治療薬市場の概要 - 製品の定義 - がん治療薬のタイプ別セグメント - 世界のがん治療薬市場規模：タイプ別分析（化学療法薬品、分子標的治療薬品、免疫療法薬品、ホルモン療法薬品、その他） - がん治療薬の用途別セグメント - 世界のがん治療薬市場規模：用途別分析（血液がん、乳がん、消化器がん、前立腺がん、肺がん、その他） - 世界のがん治療薬市場規模予測（2018年-2029年） - がん治療薬の平均価格推移（2018年-2029年） - 前提条件と制限事項 ・メーカー別競争状況 - メーカー別市場シェア - 世界の主要メーカー、業界ランキング分析 - メーカー別平均価格 - がん治療薬市場の競争状況およびトレンド ・がん治療薬の地域別市場規模 - 北米のがん治療薬市場規模（2018年-2029年） - アメリカのがん治療薬市場規模（2018年-2029年） - ヨーロッパのがん治療薬市場規模（2018年-2029年） - アジア太平洋のがん治療薬市場規模（2018年-2029年） - 中国のがん治療薬市場規模（2018年-2029年） - 日本のがん治療薬市場規模（2018年-2029年） - 韓国のがん治療薬市場規模（2018年-2029年） - インドのがん治療薬市場規模（2018年-2029年） - オーストラリアのがん治療薬市場規模（2018年-2029年） - 中南米のがん治療薬市場規模（2018年-2029年） - 中東・アフリカのがん治療薬市場規模（2018年-2029年） ・タイプ別セグメント：化学療法薬品、分子標的治療薬品、免疫療法薬品、ホルモン療法薬品、その他 - 世界のがん治療薬のタイプ別販売量（2018年-2023年） - 世界のがん治療薬のタイプ別売上（2018年-2023年） - 世界のがん治療薬のタイプ別価格 ・用途別セグメント：血液がん、乳がん、消化器がん、前立腺がん、肺がん、その他 - 世界のがん治療薬の用途別販売量（2018年-2023年） - 世界のがん治療薬の用途別売上（2018年-2023年） - 世界のがん治療薬の用途別価格 ・主要企業のプロファイル：企業情報、事業概要、売上、製品ポートフォリオ、動向 Novartis AG、CELGENE CORPORATION、Merck & Company Inc、Pfizer Inc.、Johnson & Johnson、Roche、GlaxoSmithKline plc、AstraZeneca、Teva Pharmaceutical Industries Ltd、Takeda、Astellas、NATCO Pharma Limited、Amgen、Ipsen、Aurobindo Pharma、Hikma Pharmaceuticals PLC、Mylan、Sanofi、Bayer、Biogen Idec ・産業チェーンと販売チャネルの分析 - がん治療薬産業チェーン分析 - がん治療薬の主要原材料 - がん治療薬の販売チャネル - がん治療薬のディストリビューター - がん治療薬の主要顧客 ・がん治療薬市場ダイナミクス - がん治療薬の業界動向 - がん治療薬市場の成長ドライバ、課題、阻害要因 ・調査成果および結論 ・調査方法とデータソース |
Highlights
The global Treat Oncology Drug market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Treat Oncology Drug is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Treat Oncology Drug is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Treat Oncology Drug include Novartis AG, CELGENE CORPORATION, Merck & Company Inc, Pfizer Inc., Johnson & Johnson, Roche, GlaxoSmithKline plc, AstraZeneca and Teva Pharmaceutical Industries Ltd, etc. in 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Treat Oncology Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Treat Oncology Drug.
The Treat Oncology Drug market size, estimations, and forecasts are provided in terms of sales volume (Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Treat Oncology Drug market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Treat Oncology Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Novartis AG
CELGENE CORPORATION
Merck & Company Inc
Pfizer Inc.
Johnson & Johnson
Roche
GlaxoSmithKline plc
AstraZeneca
Teva Pharmaceutical Industries Ltd
Takeda
Astellas
NATCO Pharma Limited
Amgen
Ipsen
Aurobindo Pharma
Hikma Pharmaceuticals PLC
Mylan
Sanofi
Bayer
Biogen Idec
Segment by Type
Chemotherapy Drug
Targeted Therapy Drug
Immunotherapy Drug
Hormone Therapy Drug
Others
Segment by Application
Blood Cancer
Breast Cancer
Gastrointestinal Cancer
Prostate Cancer
Lung Cancer
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Treat Oncology Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Treat Oncology Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
1 Treat Oncology Drug Market Overview
1.1 Product Overview and Scope of Treat Oncology Drug
1.2 Treat Oncology Drug Segment by Type
1.2.1 Global Treat Oncology Drug Market Value Comparison by Type (2023-2029)
1.2.2 Chemotherapy Drug
1.2.3 Targeted Therapy Drug
1.2.4 Immunotherapy Drug
1.2.5 Hormone Therapy Drug
1.2.6 Others
1.3 Treat Oncology Drug Segment by Application
1.3.1 Global Treat Oncology Drug Market Value by Application: (2023-2029)
1.3.2 Blood Cancer
1.3.3 Breast Cancer
1.3.4 Gastrointestinal Cancer
1.3.5 Prostate Cancer
1.3.6 Lung Cancer
1.3.7 Others
1.4 Global Treat Oncology Drug Market Size Estimates and Forecasts
1.4.1 Global Treat Oncology Drug Revenue 2018-2029
1.4.2 Global Treat Oncology Drug Sales 2018-2029
1.4.3 Global Treat Oncology Drug Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Treat Oncology Drug Market Competition by Manufacturers
2.1 Global Treat Oncology Drug Sales Market Share by Manufacturers (2018-2023)
2.2 Global Treat Oncology Drug Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Treat Oncology Drug Average Price by Manufacturers (2018-2023)
2.4 Global Treat Oncology Drug Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Treat Oncology Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Treat Oncology Drug, Product Type & Application
2.7 Treat Oncology Drug Market Competitive Situation and Trends
2.7.1 Treat Oncology Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Treat Oncology Drug Players Market Share by Revenue
2.7.3 Global Treat Oncology Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Treat Oncology Drug Retrospective Market Scenario by Region
3.1 Global Treat Oncology Drug Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Treat Oncology Drug Global Treat Oncology Drug Sales by Region: 2018-2029
3.2.1 Global Treat Oncology Drug Sales by Region: 2018-2023
3.2.2 Global Treat Oncology Drug Sales by Region: 2024-2029
3.3 Global Treat Oncology Drug Global Treat Oncology Drug Revenue by Region: 2018-2029
3.3.1 Global Treat Oncology Drug Revenue by Region: 2018-2023
3.3.2 Global Treat Oncology Drug Revenue by Region: 2024-2029
3.4 North America Treat Oncology Drug Market Facts & Figures by Country
3.4.1 North America Treat Oncology Drug Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Treat Oncology Drug Sales by Country (2018-2029)
3.4.3 North America Treat Oncology Drug Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Treat Oncology Drug Market Facts & Figures by Country
3.5.1 Europe Treat Oncology Drug Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Treat Oncology Drug Sales by Country (2018-2029)
3.5.3 Europe Treat Oncology Drug Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Treat Oncology Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Treat Oncology Drug Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Treat Oncology Drug Sales by Country (2018-2029)
3.6.3 Asia Pacific Treat Oncology Drug Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Treat Oncology Drug Market Facts & Figures by Country
3.7.1 Latin America Treat Oncology Drug Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Treat Oncology Drug Sales by Country (2018-2029)
3.7.3 Latin America Treat Oncology Drug Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Treat Oncology Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Treat Oncology Drug Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Treat Oncology Drug Sales by Country (2018-2029)
3.8.3 Middle East and Africa Treat Oncology Drug Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Treat Oncology Drug Sales by Type (2018-2029)
4.1.1 Global Treat Oncology Drug Sales by Type (2018-2023)
4.1.2 Global Treat Oncology Drug Sales by Type (2024-2029)
4.1.3 Global Treat Oncology Drug Sales Market Share by Type (2018-2029)
4.2 Global Treat Oncology Drug Revenue by Type (2018-2029)
4.2.1 Global Treat Oncology Drug Revenue by Type (2018-2023)
4.2.2 Global Treat Oncology Drug Revenue by Type (2024-2029)
4.2.3 Global Treat Oncology Drug Revenue Market Share by Type (2018-2029)
4.3 Global Treat Oncology Drug Price by Type (2018-2029)
5 Segment by Application
5.1 Global Treat Oncology Drug Sales by Application (2018-2029)
5.1.1 Global Treat Oncology Drug Sales by Application (2018-2023)
5.1.2 Global Treat Oncology Drug Sales by Application (2024-2029)
5.1.3 Global Treat Oncology Drug Sales Market Share by Application (2018-2029)
5.2 Global Treat Oncology Drug Revenue by Application (2018-2029)
5.2.1 Global Treat Oncology Drug Revenue by Application (2018-2023)
5.2.2 Global Treat Oncology Drug Revenue by Application (2024-2029)
5.2.3 Global Treat Oncology Drug Revenue Market Share by Application (2018-2029)
5.3 Global Treat Oncology Drug Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Novartis AG
6.1.1 Novartis AG Corporation Information
6.1.2 Novartis AG Description and Business Overview
6.1.3 Novartis AG Treat Oncology Drug Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Novartis AG Treat Oncology Drug Product Portfolio
6.1.5 Novartis AG Recent Developments/Updates
6.2 CELGENE CORPORATION
6.2.1 CELGENE CORPORATION Corporation Information
6.2.2 CELGENE CORPORATION Description and Business Overview
6.2.3 CELGENE CORPORATION Treat Oncology Drug Sales, Revenue and Gross Margin (2018-2023)
6.2.4 CELGENE CORPORATION Treat Oncology Drug Product Portfolio
6.2.5 CELGENE CORPORATION Recent Developments/Updates
6.3 Merck & Company Inc
6.3.1 Merck & Company Inc Corporation Information
6.3.2 Merck & Company Inc Description and Business Overview
6.3.3 Merck & Company Inc Treat Oncology Drug Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Merck & Company Inc Treat Oncology Drug Product Portfolio
6.3.5 Merck & Company Inc Recent Developments/Updates
6.4 Pfizer Inc.
6.4.1 Pfizer Inc. Corporation Information
6.4.2 Pfizer Inc. Description and Business Overview
6.4.3 Pfizer Inc. Treat Oncology Drug Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Pfizer Inc. Treat Oncology Drug Product Portfolio
6.4.5 Pfizer Inc. Recent Developments/Updates
6.5 Johnson & Johnson
6.5.1 Johnson & Johnson Corporation Information
6.5.2 Johnson & Johnson Description and Business Overview
6.5.3 Johnson & Johnson Treat Oncology Drug Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Johnson & Johnson Treat Oncology Drug Product Portfolio
6.5.5 Johnson & Johnson Recent Developments/Updates
6.6 Roche
6.6.1 Roche Corporation Information
6.6.2 Roche Description and Business Overview
6.6.3 Roche Treat Oncology Drug Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Roche Treat Oncology Drug Product Portfolio
6.6.5 Roche Recent Developments/Updates
6.7 GlaxoSmithKline plc
6.6.1 GlaxoSmithKline plc Corporation Information
6.6.2 GlaxoSmithKline plc Description and Business Overview
6.6.3 GlaxoSmithKline plc Treat Oncology Drug Sales, Revenue and Gross Margin (2018-2023)
6.4.4 GlaxoSmithKline plc Treat Oncology Drug Product Portfolio
6.7.5 GlaxoSmithKline plc Recent Developments/Updates
6.8 AstraZeneca
6.8.1 AstraZeneca Corporation Information
6.8.2 AstraZeneca Description and Business Overview
6.8.3 AstraZeneca Treat Oncology Drug Sales, Revenue and Gross Margin (2018-2023)
6.8.4 AstraZeneca Treat Oncology Drug Product Portfolio
6.8.5 AstraZeneca Recent Developments/Updates
6.9 Teva Pharmaceutical Industries Ltd
6.9.1 Teva Pharmaceutical Industries Ltd Corporation Information
6.9.2 Teva Pharmaceutical Industries Ltd Description and Business Overview
6.9.3 Teva Pharmaceutical Industries Ltd Treat Oncology Drug Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Teva Pharmaceutical Industries Ltd Treat Oncology Drug Product Portfolio
6.9.5 Teva Pharmaceutical Industries Ltd Recent Developments/Updates
6.10 Takeda
6.10.1 Takeda Corporation Information
6.10.2 Takeda Description and Business Overview
6.10.3 Takeda Treat Oncology Drug Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Takeda Treat Oncology Drug Product Portfolio
6.10.5 Takeda Recent Developments/Updates
6.11 Astellas
6.11.1 Astellas Corporation Information
6.11.2 Astellas Treat Oncology Drug Description and Business Overview
6.11.3 Astellas Treat Oncology Drug Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Astellas Treat Oncology Drug Product Portfolio
6.11.5 Astellas Recent Developments/Updates
6.12 NATCO Pharma Limited
6.12.1 NATCO Pharma Limited Corporation Information
6.12.2 NATCO Pharma Limited Treat Oncology Drug Description and Business Overview
6.12.3 NATCO Pharma Limited Treat Oncology Drug Sales, Revenue and Gross Margin (2018-2023)
6.12.4 NATCO Pharma Limited Treat Oncology Drug Product Portfolio
6.12.5 NATCO Pharma Limited Recent Developments/Updates
6.13 Amgen
6.13.1 Amgen Corporation Information
6.13.2 Amgen Treat Oncology Drug Description and Business Overview
6.13.3 Amgen Treat Oncology Drug Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Amgen Treat Oncology Drug Product Portfolio
6.13.5 Amgen Recent Developments/Updates
6.14 Ipsen
6.14.1 Ipsen Corporation Information
6.14.2 Ipsen Treat Oncology Drug Description and Business Overview
6.14.3 Ipsen Treat Oncology Drug Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Ipsen Treat Oncology Drug Product Portfolio
6.14.5 Ipsen Recent Developments/Updates
6.15 Aurobindo Pharma
6.15.1 Aurobindo Pharma Corporation Information
6.15.2 Aurobindo Pharma Treat Oncology Drug Description and Business Overview
6.15.3 Aurobindo Pharma Treat Oncology Drug Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Aurobindo Pharma Treat Oncology Drug Product Portfolio
6.15.5 Aurobindo Pharma Recent Developments/Updates
6.16 Hikma Pharmaceuticals PLC
6.16.1 Hikma Pharmaceuticals PLC Corporation Information
6.16.2 Hikma Pharmaceuticals PLC Treat Oncology Drug Description and Business Overview
6.16.3 Hikma Pharmaceuticals PLC Treat Oncology Drug Sales, Revenue and Gross Margin (2018-2023)
6.16.4 Hikma Pharmaceuticals PLC Treat Oncology Drug Product Portfolio
6.16.5 Hikma Pharmaceuticals PLC Recent Developments/Updates
6.17 Mylan
6.17.1 Mylan Corporation Information
6.17.2 Mylan Treat Oncology Drug Description and Business Overview
6.17.3 Mylan Treat Oncology Drug Sales, Revenue and Gross Margin (2018-2023)
6.17.4 Mylan Treat Oncology Drug Product Portfolio
6.17.5 Mylan Recent Developments/Updates
6.18 Sanofi
6.18.1 Sanofi Corporation Information
6.18.2 Sanofi Treat Oncology Drug Description and Business Overview
6.18.3 Sanofi Treat Oncology Drug Sales, Revenue and Gross Margin (2018-2023)
6.18.4 Sanofi Treat Oncology Drug Product Portfolio
6.18.5 Sanofi Recent Developments/Updates
6.19 Bayer
6.19.1 Bayer Corporation Information
6.19.2 Bayer Treat Oncology Drug Description and Business Overview
6.19.3 Bayer Treat Oncology Drug Sales, Revenue and Gross Margin (2018-2023)
6.19.4 Bayer Treat Oncology Drug Product Portfolio
6.19.5 Bayer Recent Developments/Updates
6.20 Biogen Idec
6.20.1 Biogen Idec Corporation Information
6.20.2 Biogen Idec Treat Oncology Drug Description and Business Overview
6.20.3 Biogen Idec Treat Oncology Drug Sales, Revenue and Gross Margin (2018-2023)
6.20.4 Biogen Idec Treat Oncology Drug Product Portfolio
6.20.5 Biogen Idec Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Treat Oncology Drug Industry Chain Analysis
7.2 Treat Oncology Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Treat Oncology Drug Production Mode & Process
7.4 Treat Oncology Drug Sales and Marketing
7.4.1 Treat Oncology Drug Sales Channels
7.4.2 Treat Oncology Drug Distributors
7.5 Treat Oncology Drug Customers
8 Treat Oncology Drug Market Dynamics
8.1 Treat Oncology Drug Industry Trends
8.2 Treat Oncology Drug Market Drivers
8.3 Treat Oncology Drug Market Challenges
8.4 Treat Oncology Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer